Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Share-based Compensation (2016 - 2025)

Apyx Medical's Share-based Compensation history spans 15 years, with the latest figure at $500000.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 40.33% year-over-year to $500000.0; the TTM value through Dec 2025 reached $2.0 million, down 50.14%, while the annual FY2025 figure was $2.0 million, 50.14% down from the prior year.
  • Share-based Compensation reached $500000.0 in Q4 2025 per APYX's latest filing, down from $530000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.7 million in Q2 2022 to a low of $451000.0 in Q1 2025.
  • Average Share-based Compensation over 5 years is $1.1 million, with a median of $1.2 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: skyrocketed 42.91% in 2022, then tumbled 60.02% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $1.3 million in 2021, then increased by 22.37% to $1.6 million in 2022, then tumbled by 44.3% to $914000.0 in 2023, then decreased by 8.32% to $838000.0 in 2024, then plummeted by 40.33% to $500000.0 in 2025.
  • Per Business Quant, the three most recent readings for APYX's Share-based Compensation are $500000.0 (Q4 2025), $530000.0 (Q3 2025), and $520000.0 (Q2 2025).